Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
This study identifies distinct tumor immune microenvironment subgroups in diffuse large B-cell lymphoma based on CD163 and CD11c expression, revealing prognostic significance and potential therapeutic stratification with checkpoint inhibito
CD79B expression in diffuse large B-cell lymphoma (DLBCL) exhibits a distinct gradient aligned with cell-of-origin subtypes and germinal center B-cell differentiation stages, highlighting the biological basis for differential therapy respon
Tisagenlecleucel CAR T-cell therapy demonstrates durable responses and manageable safety in adults with relapsed or refractory diffuse large B-cell lymphoma, with 5-year data supporting its curative potential in select patients.
The POLARIX trial demonstrates superior progression-free survival with Pola-R-CHP in untreated DLBCL, highlighting the utility of patient-reported outcomes alongside clinician-reported adverse events to capture symptom burden and quality of